COST-EFFECTIVENESS OF ANTI-BCMA CAR T-CELL THERAPY IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

被引：0

作者：

Barnes, J., I ^{[1
]}

Frosch, Z. A. ^{[2
]}

Garfall, A. L. ^{[3
]}

Vogl, D. ^{[3
]}

Lin, J. ^{[3
]}

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] Univ Penn, Philadelphia, PA 19104 USA

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE41

引用

页码：S343 / S343

页数：1

共 50 条

[31] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Wang, Qingming
Wei, Runhong
Guo, Shufang
Min, Chao
Zhong, Xiong
Huang, Hui
Cheng, Zhi
CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
[32] A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
An, Gang
Xu, Yan
Yi, Shuhua
Lyu, Rui
Huang, Jiaqi
Li, Wensi
Zhang, Yiran
Lan, Liping
Qiu, Lugui
BLOOD, 2024, 144 : 7235 - 7236
[33] BELANTAMAB MAFODOTIN AS THE FIRST-IN-CLASS ANTI-BCMA TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A BUDGET IMPACT AND COST-EFFECTIVENESS ANALYSIS
Speranza, G.
Diliberto, M. J.
Fattore, C.
Fiorentino, F.
Prawitz, T.
Nikolaou, A.
Samele, R.
VALUE IN HEALTH, 2022, 25 (01) : S74 - S75
[34] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Qingming Wang
Runhong Wei
Shufang Guo
Chao Min
Xiong Zhong
Hui Huang
Zhi Cheng
Cancer Gene Therapy, 2024, 31 : 420 - 426
[35] Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Deng, Haobin
Liu, Meijing
Yuan, Ting
Zhang, Huan
Cui, Rui
Li, Jingyi
Yuan, Jijun
Wang, Xiaofang
Wang, Yafei
Deng, Qi
FRONTIERS IN IMMUNOLOGY, 2021, 12
[36] Development of KITE-585: A Fully Human Anti-BCMA CAR T-Cell Therapy for the Treatment of Multiple Myeloma
Adams, Gregor B.
Feng, Jun
Ghogha, Atefeh
Mardiros, Armen
Murakami, Jodi
Phung, Tammy
Rodriguez, Ruben
Sievers, Stuart
Spindler, Tassja J.
Wiltzius, Jed
Yarka, Clare
Yoder, Sean C.
Polverino, Tony
MOLECULAR THERAPY, 2017, 25 (05) : 133 - 133
[37] Real world single center expeirence of long-term toxicities with anti-BCMA CAR T-cell therapy in relapsed and refractory multiple myeloma
Costello, Patrick
Laubach, Jacob
Mo, Clifton
Sperling, Adam
Nikiforow, Sarah
Redd, Robert
Ramsdell, Linda
Finn, Kathleen
Desnoyers, Lauren
Denisco, Michelle
Fraser, Esther
Bianchi, Giada
Hartley-Brown, Monique
Ghobrial, Irene
Richardson, Paul
Anderson, Kenneth
Munshi, Nikhil
Nadeem, Omar
Midha, Shonali
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S54 - S54
[38] Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA
Carleton, Mia
Hosoya, Hitomi
Tanaka, Kailee L.
Sworder, Brian
Hovanky, Vanna
Sahaf, Bita
Frank, Matthew J.
Duran, George E.
Zhang, Tian Y.
Arai, Sally
Iberri, David
Liedtke, Michaela
Miklos, David B.
Khodadoust, Michael S.
Sidana, Surbhi
Kurtz, David M.
CANCER RESEARCH, 2023, 83 (07)
[39] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
Arora, Sankalp
Giri, Smith
Godby, Kelly Nicole
Ravi, Gayathri
Costa, Luciano J.
Bal, Susan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy
Waldschmidt, Johannes M.
Arora, Sankalp
Vijaykumar, Tushara
Sotudeh, Noori
Anand, Praveen
Stuart, Hannah
Frede, Julia
Campbell, Tim
Kaiser, Shari M.
Lamba, Manisha
Munshi, Nikhil C.
Anderson, Kenneth C.
Yee, Andrew J.
Knoechel, Birgit
Lohr, Jens G.
Raje, Noopur
BLOOD, 2022, 140 : 9925 - 9926

← 1 2 3 4 5 →